In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the volsurf approach

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3531-3539

  Dong, Dong ^a   Wu, Baojian ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Drug metabolism; Enzymes; In silico modeling; Molecular fields; QSAR; UGT; VolSurf

Indexed keywords

3 HYDROXYBENZO[A]PYRENE; 4 HYDROXYINDOLE; 4 NITROPHENOL; 7 HYDROXYBENZO[A]PYRENE; 7 HYDROXYWARFARIN; ALDOSTERONE; ALIZARIN; APIGENIN; CANNABINOL; COUMARIN ANTICOAGULANT; DOPAMINE; ENDOXIFEN; ENTACAPONE; ETHINYLESTRADIOL; FERULIC ACID; GENISTEIN; GLUCURONOSYLTRANSFERASE 1A10; HESPERETIN; HYMECROMONE; INDOLE DERIVATIVE; ISOLIQUIRITIGENIN; MAGNOLOL; NEBICAPONE; OROXYLIN A; PHENOL DERIVATIVE; PICEATANNOL; PICROSIDE II; PLANT GLYCOSIDE; RALOXIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG METABOLISM; DRUG STABILITY; ENZYME ACTIVITY; ENZYME SUBSTRATE; HYDROPHILICITY; HYDROPHOBICITY; PARTIAL LEAST SQUARES REGRESSION; PHARMACOLOGICAL PARAMETERS; POLARIZATION; PREDICTION; VOLSURF METHOD;

EID: 84864050952     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23100     Document Type: Article

References (47)

1. Sheweita SA. 2000. Drug-metabolizing enzymes: Mechanisms and functions. Curr Drug Metab 1(2):107-132.
2. Tolson AH, Wang H. 2010. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62(13):1238-1249.
3. Mizuma T. 2009. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378(1-2):140-141.
4. Jeong EJ, Liu Y, Lin H, Hu M. 2005. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: Role of UGT1A10. Drug Metab Dispos 33(6):785-794.
5. Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, Kume T. 2011. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos 39(9):1495-1502.
6. Zhu L, Ge G, Zhang H, Liu H, He G, Liang S, Zhang Y, Fang Z, Dong P, Finel M, Yang L. 2012. Characterization of hepatic and intestinal glucuronidation of magnolol: Application of the RAF approach to decipher the contributions of multiple UGT isoforms. Drug Metab Dispos 40(3):529-538.
7. Shiraga T, Yajima K, Suzuki K, Suzuki K, Hashimoto T, Iwatsubo T, Miyashita A, Usui T. 2012. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine. Drug Metab Dispos 40(2):276-282.
8. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. 2006. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: Decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 34(6):943-949.
9. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. 2007. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 28(11):2412-2418.
10. Sorich MJ, Smith PA, McKinnon RA, Miners JO. 2002. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12(8):635-645.
11. Smith PA, Sorich MJ, McKinnon RA, Miners JO. 2003. Pharmacophore and quantitative structure-activity relationship modeling: Complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 46(9):1617-1626.
12. Smith PA, Sorich MJ, Low LS, McKinnon RA, Miners JO. 2004. Towards integrated ADME prediction: Past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J Mol Graph Model 22(6):507-517.
13. Balliet RM, Chen G, Dellinger RW, Lazarus P. 2010. UDP-glucuronosyltransferase 1A10: Activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility. Drug Metab Dispos 38(3):484-490.
14. Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, Radominska-Pandya A. 2006. Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. Biochemistry 45(7):2322-2332.
15. Höglund C, Sneitz N, Radominska-Pandya A, Laakonen L, Finel M. 2011. Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens. Steroids 76(13):1465-1473.
16. Lewinsky RH, Smith PA, Mackenzie PI. 2005. Glucuronidation of bioflavonoids by human UGT1A10: Structure-function relationships. Xenobiotica 35(2):117-129.
17. Wu B, Morrow JK, Singh R, Zhang S, Hu M. 2011. Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther 336(2):403-413.
18. Cruciani G, Crivori P, Carrupt P-A, Testa B. 2000. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach. J Mol Struct: THEOCHEM 503(1-2):17-30.
19. Cruciani G, Pastor M, Guba W. 2000. VolSurf: A new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci Suppl 2:S29-S39.
20. Cramer RD, Patterson DE, Bunce JD. 1988. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110(18):5959-5967.
21. Langer T, Hoffmann RD, Eds. 2006. Pharmacophores and pharmacophore searches. Weinheim: Wiley-VCH.
22. Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, Finel M. 2010. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos 38(3):386-395.
23. Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A. 2008. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: Phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metab Dispos 36(11):2211-2218.
24. Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. 2009. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs. Br J Clin Pharmacol 68(3):402-412.
25. Cheng Z, Radominska-Pandya A, Tephly TR. 1999. Studies on the substrate specificity of human intestinal UDP-lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27(10):1165-1170.
26. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH. 2009. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37(7):1496-1504.
27. Itäaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, Finel M. 2009. Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 37(4):768-775.
28. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, Lazarus P. 2009. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69(5):1892-1900.
29. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M. 2005. Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 33(7):1017-1026.
30. Li X, Shang L, Wu Y, Abbas S, Li D, Netter P, Ouzzine M, Wang H, Magdalou J. 2011. Identification of the human UDP-glucuronosyltransferase isoforms involved in the glucuronidation of the phytochemical ferulic acid. Drug Metab Pharmacokinet. 26(4):341-350.
31. Tang L, Singh R, Liu Z, Hu M. 2009. Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol Pharm 6(5):1466-1482.
32. Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, Barron D, Meinl W, Glatt H, Williamson G, van Bladeren PJ, Rietjens IM. 2010. Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 38(4):617-625.
33. Maul R, Siegl D, Kulling SE. 2011. Glucuronidation of the red clover isoflavone irilone by liver microsomes from different species and human UDP-glucuronosyltransferases. Drug Metab Dispos 39(4):610-616.
34. Guo J, Liu A, Cao H, Luo Y, Pezzuto JM, van Breemen RB. 2008. Biotransformation of the chemopreventive agent 2′, 4′, 4-trihydroxychalcone (isoliquiritigenin) by UDP-glucuronosyltransferases. Drug Metab Dispos 36(10):2104-2112.
35. Song WY, Ji HY, Baek NI, Jeong TS, Lee HS. 2010. In vitro metabolism of jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes. Arch Pharm Res 33(12):1985-1996.
36. Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Almeida L, Wright LC, Soares-Da-Silva P. 2006. Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: Characterization of in vitro glucuronidation. Drug Metab Dispos 34(11):1856-1862.
37. Zhou Q, Zheng Z, Xia B, Tang L, Lv C, Liu W, Liu Z, Hu M. 2010. Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes. Pharm Res 27(8):1568-1583.
38. Miksits M, Maier-Salamon A, Vo TP, Sulyok M, Schuhmacher R, Szekeres T, Jäger W. 2010. Glucuronidation of piceatannol by human liver microsomes: Major role of UGT1A1, UGT1A8 and UGT1A10. J Pharm Pharmacol 62(1):47-54.
39. Li T, Zheng Y, Fu F, Ji H, Chen X, Zhao Y, Zhao D, Li N, Zhang L. 2011. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs. Xenobiotica 41(7):530-537.
40. Temp DC, Fan PW, Stevens JC. 2002. Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30(6):694-700.
41. Sten T, Qvisen S, Uutela P, Luukkanen L, Kostiainen R, Finel M. 2006. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos 34(9):1488-1494.
42. Watanabe Y, Nakajima M, Yokoi T. 2002. Troglitazone glucuronidation in human liver and intestine microsomes: High catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30(12):1462-1469.
43. Argikar UA, Remmel RP. 2009. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37(1):229-236.
44. Basu NK, Kubota S, Meselhy MR, Ciotti M, Chowdhury B, Hartori M, Owens IS. 2004. Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem 279(27):28320-28329.
45. Iwuchukwu OF, Nagar S. 2010. Cis-resveratrol glucuronidation kinetics in human and recombinant UGT1A sources. Xenobiotica 40(2):102-108.
46. Rowland A, Knights KM, Mackenzie PI, Miners JO. 2008. The "albumin effect" and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36(6):1056-1062.
47. Crivori P, Cruciani G, Carrupt PA, Testa B. 2000. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 43(11):2204-2216.